Follow us on:

Linkedin Facebook

Open Orphan Investor Presentation Feb 2020

Open Orphan plc (LON:ORPH) Co-Founder and Executive Chairman Cathal Friel talks us though the Feb 2020 Investor Presentation.

Open Orphan was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). In June 2019 Open Orphan acquired AIM-listed Venn Life Sciences plc in a reverse take-over and in January 2020 completed a merger with hVIVO plc.

Open Orphan (ORPH) is quoted on both the AIM and Euronext Growth markets.

Share this presentation

Twitter
LinkedIn
Facebook
Email
WhatsApp

More News

Open Orphan
Open Orphan Investor Presentation Feb 2020

Other Company Presentations

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.